Global Neuraminidase Inhibitors Drug Market Research Report 2024(Status and Outlook)
Report Overview:
Neuraminidase Inhibitors (NAIs) are the type of drugs that are used to block the neuraminidase enzyme.
The Global Neuraminidase Inhibitors Drug Market Size was estimated at USD 985.04 million in 2023 and is projected to reach USD 1389.41 million by 2029, exhibiting a CAGR of 5.90% during the forecast period.
This report provides a deep insight into the global Neuraminidase Inhibitors Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neuraminidase Inhibitors Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neuraminidase Inhibitors Drug market in any manner.
Global Neuraminidase Inhibitors Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Roche
GSK
Gilead Sciences
Daiichi Sankyo
AstraZeneca
Pfizer
Teva
Bristol-Myers Squibb
Sun Pharmaceutical
Market Segmentation (by Type)
Oseltamivir
Zanamivir
Peramivir
Laninamivir
Market Segmentation (by Application)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Geographic Segmentation
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neuraminidase Inhibitors Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Neuraminidase Inhibitors (NAIs) are the type of drugs that are used to block the neuraminidase enzyme.
The Global Neuraminidase Inhibitors Drug Market Size was estimated at USD 985.04 million in 2023 and is projected to reach USD 1389.41 million by 2029, exhibiting a CAGR of 5.90% during the forecast period.
This report provides a deep insight into the global Neuraminidase Inhibitors Drug market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Neuraminidase Inhibitors Drug Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Neuraminidase Inhibitors Drug market in any manner.
Global Neuraminidase Inhibitors Drug Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
Roche
GSK
Gilead Sciences
Daiichi Sankyo
AstraZeneca
Pfizer
Teva
Bristol-Myers Squibb
Sun Pharmaceutical
Market Segmentation (by Type)
Oseltamivir
Zanamivir
Peramivir
Laninamivir
Market Segmentation (by Application)
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others
Geographic Segmentation
- North America (USA, Canada, Mexico)
- Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
- South America (Brazil, Argentina, Columbia, Rest of South America)
- The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Neuraminidase Inhibitors Drug Market
- Overview of the regional outlook of the Neuraminidase Inhibitors Drug Market:
- Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
- This enables you to anticipate market changes to remain ahead of your competitors
- You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
- The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
- Provision of market value (USD Billion) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
- Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
- Provides insight into the market through Value Chain
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- 6-month post-sales analyst support
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Neuraminidase Inhibitors Drug Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Market's Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE
1.1 Market Definition and Statistical Scope of Neuraminidase Inhibitors Drug
1.2 Key Market Segments
1.2.1 Neuraminidase Inhibitors Drug Segment by Type
1.2.2 Neuraminidase Inhibitors Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURAMINIDASE INHIBITORS DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neuraminidase Inhibitors Drug Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Neuraminidase Inhibitors Drug Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURAMINIDASE INHIBITORS DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Global Neuraminidase Inhibitors Drug Sales by Manufacturers (2019-2024)
3.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Manufacturers (2019-2024)
3.3 Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Neuraminidase Inhibitors Drug Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Neuraminidase Inhibitors Drug Sales Sites, Area Served, Product Type
3.6 Neuraminidase Inhibitors Drug Market Competitive Situation and Trends
3.6.1 Neuraminidase Inhibitors Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neuraminidase Inhibitors Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NEURAMINIDASE INHIBITORS DRUG INDUSTRY CHAIN ANALYSIS
4.1 Neuraminidase Inhibitors Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURAMINIDASE INHIBITORS DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NEURAMINIDASE INHIBITORS DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neuraminidase Inhibitors Drug Sales Market Share by Type (2019-2024)
6.3 Global Neuraminidase Inhibitors Drug Market Size Market Share by Type (2019-2024)
6.4 Global Neuraminidase Inhibitors Drug Price by Type (2019-2024)
7 NEURAMINIDASE INHIBITORS DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neuraminidase Inhibitors Drug Market Sales by Application (2019-2024)
7.3 Global Neuraminidase Inhibitors Drug Market Size (M USD) by Application (2019-2024)
7.4 Global Neuraminidase Inhibitors Drug Sales Growth Rate by Application (2019-2024)
8 NEURAMINIDASE INHIBITORS DRUG MARKET SEGMENTATION BY REGION
8.1 Global Neuraminidase Inhibitors Drug Sales by Region
8.1.1 Global Neuraminidase Inhibitors Drug Sales by Region
8.1.2 Global Neuraminidase Inhibitors Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Neuraminidase Inhibitors Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neuraminidase Inhibitors Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Neuraminidase Inhibitors Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neuraminidase Inhibitors Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neuraminidase Inhibitors Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Roche
9.1.1 Roche Neuraminidase Inhibitors Drug Basic Information
9.1.2 Roche Neuraminidase Inhibitors Drug Product Overview
9.1.3 Roche Neuraminidase Inhibitors Drug Product Market Performance
9.1.4 Roche Business Overview
9.1.5 Roche Neuraminidase Inhibitors Drug SWOT Analysis
9.1.6 Roche Recent Developments
9.2 GSK
9.2.1 GSK Neuraminidase Inhibitors Drug Basic Information
9.2.2 GSK Neuraminidase Inhibitors Drug Product Overview
9.2.3 GSK Neuraminidase Inhibitors Drug Product Market Performance
9.2.4 GSK Business Overview
9.2.5 GSK Neuraminidase Inhibitors Drug SWOT Analysis
9.2.6 GSK Recent Developments
9.3 Gilead Sciences
9.3.1 Gilead Sciences Neuraminidase Inhibitors Drug Basic Information
9.3.2 Gilead Sciences Neuraminidase Inhibitors Drug Product Overview
9.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Product Market Performance
9.3.4 Gilead Sciences Neuraminidase Inhibitors Drug SWOT Analysis
9.3.5 Gilead Sciences Business Overview
9.3.6 Gilead Sciences Recent Developments
9.4 Daiichi Sankyo
9.4.1 Daiichi Sankyo Neuraminidase Inhibitors Drug Basic Information
9.4.2 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Overview
9.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Market Performance
9.4.4 Daiichi Sankyo Business Overview
9.4.5 Daiichi Sankyo Recent Developments
9.5 AstraZeneca
9.5.1 AstraZeneca Neuraminidase Inhibitors Drug Basic Information
9.5.2 AstraZeneca Neuraminidase Inhibitors Drug Product Overview
9.5.3 AstraZeneca Neuraminidase Inhibitors Drug Product Market Performance
9.5.4 AstraZeneca Business Overview
9.5.5 AstraZeneca Recent Developments
9.6 Pfizer
9.6.1 Pfizer Neuraminidase Inhibitors Drug Basic Information
9.6.2 Pfizer Neuraminidase Inhibitors Drug Product Overview
9.6.3 Pfizer Neuraminidase Inhibitors Drug Product Market Performance
9.6.4 Pfizer Business Overview
9.6.5 Pfizer Recent Developments
9.7 Teva
9.7.1 Teva Neuraminidase Inhibitors Drug Basic Information
9.7.2 Teva Neuraminidase Inhibitors Drug Product Overview
9.7.3 Teva Neuraminidase Inhibitors Drug Product Market Performance
9.7.4 Teva Business Overview
9.7.5 Teva Recent Developments
9.8 Bristol-Myers Squibb
9.8.1 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Basic Information
9.8.2 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Overview
9.8.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Market Performance
9.8.4 Bristol-Myers Squibb Business Overview
9.8.5 Bristol-Myers Squibb Recent Developments
9.9 Sun Pharmaceutical
9.9.1 Sun Pharmaceutical Neuraminidase Inhibitors Drug Basic Information
9.9.2 Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Overview
9.9.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Market Performance
9.9.4 Sun Pharmaceutical Business Overview
9.9.5 Sun Pharmaceutical Recent Developments
10 NEURAMINIDASE INHIBITORS DRUG MARKET FORECAST BY REGION
10.1 Global Neuraminidase Inhibitors Drug Market Size Forecast
10.2 Global Neuraminidase Inhibitors Drug Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Neuraminidase Inhibitors Drug Market Size Forecast by Country
10.2.3 Asia Pacific Neuraminidase Inhibitors Drug Market Size Forecast by Region
10.2.4 South America Neuraminidase Inhibitors Drug Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Neuraminidase Inhibitors Drug Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Neuraminidase Inhibitors Drug by Type (2025-2030)
11.1.2 Global Neuraminidase Inhibitors Drug Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Neuraminidase Inhibitors Drug by Type (2025-2030)
11.2 Global Neuraminidase Inhibitors Drug Market Forecast by Application (2025-2030)
11.2.1 Global Neuraminidase Inhibitors Drug Sales (Kilotons) Forecast by Application
11.2.2 Global Neuraminidase Inhibitors Drug Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
1.1 Market Definition and Statistical Scope of Neuraminidase Inhibitors Drug
1.2 Key Market Segments
1.2.1 Neuraminidase Inhibitors Drug Segment by Type
1.2.2 Neuraminidase Inhibitors Drug Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 NEURAMINIDASE INHIBITORS DRUG MARKET OVERVIEW
2.1 Global Market Overview
2.1.1 Global Neuraminidase Inhibitors Drug Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Neuraminidase Inhibitors Drug Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 NEURAMINIDASE INHIBITORS DRUG MARKET COMPETITIVE LANDSCAPE
3.1 Global Neuraminidase Inhibitors Drug Sales by Manufacturers (2019-2024)
3.2 Global Neuraminidase Inhibitors Drug Revenue Market Share by Manufacturers (2019-2024)
3.3 Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Neuraminidase Inhibitors Drug Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Neuraminidase Inhibitors Drug Sales Sites, Area Served, Product Type
3.6 Neuraminidase Inhibitors Drug Market Competitive Situation and Trends
3.6.1 Neuraminidase Inhibitors Drug Market Concentration Rate
3.6.2 Global 5 and 10 Largest Neuraminidase Inhibitors Drug Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 NEURAMINIDASE INHIBITORS DRUG INDUSTRY CHAIN ANALYSIS
4.1 Neuraminidase Inhibitors Drug Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 THE DEVELOPMENT AND DYNAMICS OF NEURAMINIDASE INHIBITORS DRUG MARKET
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 NEURAMINIDASE INHIBITORS DRUG MARKET SEGMENTATION BY TYPE
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Neuraminidase Inhibitors Drug Sales Market Share by Type (2019-2024)
6.3 Global Neuraminidase Inhibitors Drug Market Size Market Share by Type (2019-2024)
6.4 Global Neuraminidase Inhibitors Drug Price by Type (2019-2024)
7 NEURAMINIDASE INHIBITORS DRUG MARKET SEGMENTATION BY APPLICATION
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Neuraminidase Inhibitors Drug Market Sales by Application (2019-2024)
7.3 Global Neuraminidase Inhibitors Drug Market Size (M USD) by Application (2019-2024)
7.4 Global Neuraminidase Inhibitors Drug Sales Growth Rate by Application (2019-2024)
8 NEURAMINIDASE INHIBITORS DRUG MARKET SEGMENTATION BY REGION
8.1 Global Neuraminidase Inhibitors Drug Sales by Region
8.1.1 Global Neuraminidase Inhibitors Drug Sales by Region
8.1.2 Global Neuraminidase Inhibitors Drug Sales Market Share by Region
8.2 North America
8.2.1 North America Neuraminidase Inhibitors Drug Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Neuraminidase Inhibitors Drug Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Neuraminidase Inhibitors Drug Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Neuraminidase Inhibitors Drug Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Neuraminidase Inhibitors Drug Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 KEY COMPANIES PROFILE
9.1 Roche
9.1.1 Roche Neuraminidase Inhibitors Drug Basic Information
9.1.2 Roche Neuraminidase Inhibitors Drug Product Overview
9.1.3 Roche Neuraminidase Inhibitors Drug Product Market Performance
9.1.4 Roche Business Overview
9.1.5 Roche Neuraminidase Inhibitors Drug SWOT Analysis
9.1.6 Roche Recent Developments
9.2 GSK
9.2.1 GSK Neuraminidase Inhibitors Drug Basic Information
9.2.2 GSK Neuraminidase Inhibitors Drug Product Overview
9.2.3 GSK Neuraminidase Inhibitors Drug Product Market Performance
9.2.4 GSK Business Overview
9.2.5 GSK Neuraminidase Inhibitors Drug SWOT Analysis
9.2.6 GSK Recent Developments
9.3 Gilead Sciences
9.3.1 Gilead Sciences Neuraminidase Inhibitors Drug Basic Information
9.3.2 Gilead Sciences Neuraminidase Inhibitors Drug Product Overview
9.3.3 Gilead Sciences Neuraminidase Inhibitors Drug Product Market Performance
9.3.4 Gilead Sciences Neuraminidase Inhibitors Drug SWOT Analysis
9.3.5 Gilead Sciences Business Overview
9.3.6 Gilead Sciences Recent Developments
9.4 Daiichi Sankyo
9.4.1 Daiichi Sankyo Neuraminidase Inhibitors Drug Basic Information
9.4.2 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Overview
9.4.3 Daiichi Sankyo Neuraminidase Inhibitors Drug Product Market Performance
9.4.4 Daiichi Sankyo Business Overview
9.4.5 Daiichi Sankyo Recent Developments
9.5 AstraZeneca
9.5.1 AstraZeneca Neuraminidase Inhibitors Drug Basic Information
9.5.2 AstraZeneca Neuraminidase Inhibitors Drug Product Overview
9.5.3 AstraZeneca Neuraminidase Inhibitors Drug Product Market Performance
9.5.4 AstraZeneca Business Overview
9.5.5 AstraZeneca Recent Developments
9.6 Pfizer
9.6.1 Pfizer Neuraminidase Inhibitors Drug Basic Information
9.6.2 Pfizer Neuraminidase Inhibitors Drug Product Overview
9.6.3 Pfizer Neuraminidase Inhibitors Drug Product Market Performance
9.6.4 Pfizer Business Overview
9.6.5 Pfizer Recent Developments
9.7 Teva
9.7.1 Teva Neuraminidase Inhibitors Drug Basic Information
9.7.2 Teva Neuraminidase Inhibitors Drug Product Overview
9.7.3 Teva Neuraminidase Inhibitors Drug Product Market Performance
9.7.4 Teva Business Overview
9.7.5 Teva Recent Developments
9.8 Bristol-Myers Squibb
9.8.1 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Basic Information
9.8.2 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Overview
9.8.3 Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Market Performance
9.8.4 Bristol-Myers Squibb Business Overview
9.8.5 Bristol-Myers Squibb Recent Developments
9.9 Sun Pharmaceutical
9.9.1 Sun Pharmaceutical Neuraminidase Inhibitors Drug Basic Information
9.9.2 Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Overview
9.9.3 Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Market Performance
9.9.4 Sun Pharmaceutical Business Overview
9.9.5 Sun Pharmaceutical Recent Developments
10 NEURAMINIDASE INHIBITORS DRUG MARKET FORECAST BY REGION
10.1 Global Neuraminidase Inhibitors Drug Market Size Forecast
10.2 Global Neuraminidase Inhibitors Drug Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Neuraminidase Inhibitors Drug Market Size Forecast by Country
10.2.3 Asia Pacific Neuraminidase Inhibitors Drug Market Size Forecast by Region
10.2.4 South America Neuraminidase Inhibitors Drug Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Neuraminidase Inhibitors Drug by Country
11 FORECAST MARKET BY TYPE AND BY APPLICATION (2025-2030)
11.1 Global Neuraminidase Inhibitors Drug Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Neuraminidase Inhibitors Drug by Type (2025-2030)
11.1.2 Global Neuraminidase Inhibitors Drug Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Neuraminidase Inhibitors Drug by Type (2025-2030)
11.2 Global Neuraminidase Inhibitors Drug Market Forecast by Application (2025-2030)
11.2.1 Global Neuraminidase Inhibitors Drug Sales (Kilotons) Forecast by Application
11.2.2 Global Neuraminidase Inhibitors Drug Market Size (M USD) Forecast by Application (2025-2030)
12 CONCLUSION AND KEY FINDINGS
LIST OF TABLES
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neuraminidase Inhibitors Drug Market Size Comparison by Region (M USD)
Table 5. Global Neuraminidase Inhibitors Drug Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Neuraminidase Inhibitors Drug Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Neuraminidase Inhibitors Drug Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Neuraminidase Inhibitors Drug Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
Table 10. Global Market Neuraminidase Inhibitors Drug Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Neuraminidase Inhibitors Drug Sales Sites and Area Served
Table 12. Manufacturers Neuraminidase Inhibitors Drug Product Type
Table 13. Global Neuraminidase Inhibitors Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Neuraminidase Inhibitors Drug
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neuraminidase Inhibitors Drug Market Challenges
Table 22. Global Neuraminidase Inhibitors Drug Sales by Type (Kilotons)
Table 23. Global Neuraminidase Inhibitors Drug Market Size by Type (M USD)
Table 24. Global Neuraminidase Inhibitors Drug Sales (Kilotons) by Type (2019-2024)
Table 25. Global Neuraminidase Inhibitors Drug Sales Market Share by Type (2019-2024)
Table 26. Global Neuraminidase Inhibitors Drug Market Size (M USD) by Type (2019-2024)
Table 27. Global Neuraminidase Inhibitors Drug Market Size Share by Type (2019-2024)
Table 28. Global Neuraminidase Inhibitors Drug Price (USD/Ton) by Type (2019-2024)
Table 29. Global Neuraminidase Inhibitors Drug Sales (Kilotons) by Application
Table 30. Global Neuraminidase Inhibitors Drug Market Size by Application
Table 31. Global Neuraminidase Inhibitors Drug Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Neuraminidase Inhibitors Drug Sales Market Share by Application (2019-2024)
Table 33. Global Neuraminidase Inhibitors Drug Sales by Application (2019-2024) & (M USD)
Table 34. Global Neuraminidase Inhibitors Drug Market Share by Application (2019-2024)
Table 35. Global Neuraminidase Inhibitors Drug Sales Growth Rate by Application (2019-2024)
Table 36. Global Neuraminidase Inhibitors Drug Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Neuraminidase Inhibitors Drug Sales Market Share by Region (2019-2024)
Table 38. North America Neuraminidase Inhibitors Drug Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Neuraminidase Inhibitors Drug Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Neuraminidase Inhibitors Drug Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Neuraminidase Inhibitors Drug Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Neuraminidase Inhibitors Drug Sales by Region (2019-2024) & (Kilotons)
Table 43. Roche Neuraminidase Inhibitors Drug Basic Information
Table 44. Roche Neuraminidase Inhibitors Drug Product Overview
Table 45. Roche Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Roche Business Overview
Table 47. Roche Neuraminidase Inhibitors Drug SWOT Analysis
Table 48. Roche Recent Developments
Table 49. GSK Neuraminidase Inhibitors Drug Basic Information
Table 50. GSK Neuraminidase Inhibitors Drug Product Overview
Table 51. GSK Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. GSK Business Overview
Table 53. GSK Neuraminidase Inhibitors Drug SWOT Analysis
Table 54. GSK Recent Developments
Table 55. Gilead Sciences Neuraminidase Inhibitors Drug Basic Information
Table 56. Gilead Sciences Neuraminidase Inhibitors Drug Product Overview
Table 57. Gilead Sciences Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Gilead Sciences Neuraminidase Inhibitors Drug SWOT Analysis
Table 59. Gilead Sciences Business Overview
Table 60. Gilead Sciences Recent Developments
Table 61. Daiichi Sankyo Neuraminidase Inhibitors Drug Basic Information
Table 62. Daiichi Sankyo Neuraminidase Inhibitors Drug Product Overview
Table 63. Daiichi Sankyo Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Daiichi Sankyo Business Overview
Table 65. Daiichi Sankyo Recent Developments
Table 66. AstraZeneca Neuraminidase Inhibitors Drug Basic Information
Table 67. AstraZeneca Neuraminidase Inhibitors Drug Product Overview
Table 68. AstraZeneca Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Recent Developments
Table 71. Pfizer Neuraminidase Inhibitors Drug Basic Information
Table 72. Pfizer Neuraminidase Inhibitors Drug Product Overview
Table 73. Pfizer Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Pfizer Business Overview
Table 75. Pfizer Recent Developments
Table 76. Teva Neuraminidase Inhibitors Drug Basic Information
Table 77. Teva Neuraminidase Inhibitors Drug Product Overview
Table 78. Teva Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Teva Business Overview
Table 80. Teva Recent Developments
Table 81. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Basic Information
Table 82. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Overview
Table 83. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Recent Developments
Table 86. Sun Pharmaceutical Neuraminidase Inhibitors Drug Basic Information
Table 87. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Overview
Table 88. Sun Pharmaceutical Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Sun Pharmaceutical Business Overview
Table 90. Sun Pharmaceutical Recent Developments
Table 91. Global Neuraminidase Inhibitors Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 92. Global Neuraminidase Inhibitors Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 93. North America Neuraminidase Inhibitors Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 94. North America Neuraminidase Inhibitors Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 95. Europe Neuraminidase Inhibitors Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 96. Europe Neuraminidase Inhibitors Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 97. Asia Pacific Neuraminidase Inhibitors Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 98. Asia Pacific Neuraminidase Inhibitors Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 99. South America Neuraminidase Inhibitors Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 100. South America Neuraminidase Inhibitors Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 101. Middle East and Africa Neuraminidase Inhibitors Drug Consumption Forecast by Country (2025-2030) & (Units)
Table 102. Middle East and Africa Neuraminidase Inhibitors Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 103. Global Neuraminidase Inhibitors Drug Sales Forecast by Type (2025-2030) & (Kilotons)
Table 104. Global Neuraminidase Inhibitors Drug Market Size Forecast by Type (2025-2030) & (M USD)
Table 105. Global Neuraminidase Inhibitors Drug Price Forecast by Type (2025-2030) & (USD/Ton)
Table 106. Global Neuraminidase Inhibitors Drug Sales (Kilotons) Forecast by Application (2025-2030)
Table 107. Global Neuraminidase Inhibitors Drug Market Size Forecast by Application (2025-2030) & (M USD)
Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Neuraminidase Inhibitors Drug Market Size Comparison by Region (M USD)
Table 5. Global Neuraminidase Inhibitors Drug Sales (Kilotons) by Manufacturers (2019-2024)
Table 6. Global Neuraminidase Inhibitors Drug Sales Market Share by Manufacturers (2019-2024)
Table 7. Global Neuraminidase Inhibitors Drug Revenue (M USD) by Manufacturers (2019-2024)
Table 8. Global Neuraminidase Inhibitors Drug Revenue Share by Manufacturers (2019-2024)
Table 9. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Neuraminidase Inhibitors Drug as of 2022)
Table 10. Global Market Neuraminidase Inhibitors Drug Average Price (USD/Ton) of Key Manufacturers (2019-2024)
Table 11. Manufacturers Neuraminidase Inhibitors Drug Sales Sites and Area Served
Table 12. Manufacturers Neuraminidase Inhibitors Drug Product Type
Table 13. Global Neuraminidase Inhibitors Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Mergers & Acquisitions, Expansion Plans
Table 15. Industry Chain Map of Neuraminidase Inhibitors Drug
Table 16. Market Overview of Key Raw Materials
Table 17. Midstream Market Analysis
Table 18. Downstream Customer Analysis
Table 19. Key Development Trends
Table 20. Driving Factors
Table 21. Neuraminidase Inhibitors Drug Market Challenges
Table 22. Global Neuraminidase Inhibitors Drug Sales by Type (Kilotons)
Table 23. Global Neuraminidase Inhibitors Drug Market Size by Type (M USD)
Table 24. Global Neuraminidase Inhibitors Drug Sales (Kilotons) by Type (2019-2024)
Table 25. Global Neuraminidase Inhibitors Drug Sales Market Share by Type (2019-2024)
Table 26. Global Neuraminidase Inhibitors Drug Market Size (M USD) by Type (2019-2024)
Table 27. Global Neuraminidase Inhibitors Drug Market Size Share by Type (2019-2024)
Table 28. Global Neuraminidase Inhibitors Drug Price (USD/Ton) by Type (2019-2024)
Table 29. Global Neuraminidase Inhibitors Drug Sales (Kilotons) by Application
Table 30. Global Neuraminidase Inhibitors Drug Market Size by Application
Table 31. Global Neuraminidase Inhibitors Drug Sales by Application (2019-2024) & (Kilotons)
Table 32. Global Neuraminidase Inhibitors Drug Sales Market Share by Application (2019-2024)
Table 33. Global Neuraminidase Inhibitors Drug Sales by Application (2019-2024) & (M USD)
Table 34. Global Neuraminidase Inhibitors Drug Market Share by Application (2019-2024)
Table 35. Global Neuraminidase Inhibitors Drug Sales Growth Rate by Application (2019-2024)
Table 36. Global Neuraminidase Inhibitors Drug Sales by Region (2019-2024) & (Kilotons)
Table 37. Global Neuraminidase Inhibitors Drug Sales Market Share by Region (2019-2024)
Table 38. North America Neuraminidase Inhibitors Drug Sales by Country (2019-2024) & (Kilotons)
Table 39. Europe Neuraminidase Inhibitors Drug Sales by Country (2019-2024) & (Kilotons)
Table 40. Asia Pacific Neuraminidase Inhibitors Drug Sales by Region (2019-2024) & (Kilotons)
Table 41. South America Neuraminidase Inhibitors Drug Sales by Country (2019-2024) & (Kilotons)
Table 42. Middle East and Africa Neuraminidase Inhibitors Drug Sales by Region (2019-2024) & (Kilotons)
Table 43. Roche Neuraminidase Inhibitors Drug Basic Information
Table 44. Roche Neuraminidase Inhibitors Drug Product Overview
Table 45. Roche Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 46. Roche Business Overview
Table 47. Roche Neuraminidase Inhibitors Drug SWOT Analysis
Table 48. Roche Recent Developments
Table 49. GSK Neuraminidase Inhibitors Drug Basic Information
Table 50. GSK Neuraminidase Inhibitors Drug Product Overview
Table 51. GSK Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 52. GSK Business Overview
Table 53. GSK Neuraminidase Inhibitors Drug SWOT Analysis
Table 54. GSK Recent Developments
Table 55. Gilead Sciences Neuraminidase Inhibitors Drug Basic Information
Table 56. Gilead Sciences Neuraminidase Inhibitors Drug Product Overview
Table 57. Gilead Sciences Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 58. Gilead Sciences Neuraminidase Inhibitors Drug SWOT Analysis
Table 59. Gilead Sciences Business Overview
Table 60. Gilead Sciences Recent Developments
Table 61. Daiichi Sankyo Neuraminidase Inhibitors Drug Basic Information
Table 62. Daiichi Sankyo Neuraminidase Inhibitors Drug Product Overview
Table 63. Daiichi Sankyo Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 64. Daiichi Sankyo Business Overview
Table 65. Daiichi Sankyo Recent Developments
Table 66. AstraZeneca Neuraminidase Inhibitors Drug Basic Information
Table 67. AstraZeneca Neuraminidase Inhibitors Drug Product Overview
Table 68. AstraZeneca Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Recent Developments
Table 71. Pfizer Neuraminidase Inhibitors Drug Basic Information
Table 72. Pfizer Neuraminidase Inhibitors Drug Product Overview
Table 73. Pfizer Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 74. Pfizer Business Overview
Table 75. Pfizer Recent Developments
Table 76. Teva Neuraminidase Inhibitors Drug Basic Information
Table 77. Teva Neuraminidase Inhibitors Drug Product Overview
Table 78. Teva Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 79. Teva Business Overview
Table 80. Teva Recent Developments
Table 81. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Basic Information
Table 82. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Product Overview
Table 83. Bristol-Myers Squibb Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Recent Developments
Table 86. Sun Pharmaceutical Neuraminidase Inhibitors Drug Basic Information
Table 87. Sun Pharmaceutical Neuraminidase Inhibitors Drug Product Overview
Table 88. Sun Pharmaceutical Neuraminidase Inhibitors Drug Sales (Kilotons), Revenue (M USD), Price (USD/Ton) and Gross Margin (2019-2024)
Table 89. Sun Pharmaceutical Business Overview
Table 90. Sun Pharmaceutical Recent Developments
Table 91. Global Neuraminidase Inhibitors Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 92. Global Neuraminidase Inhibitors Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 93. North America Neuraminidase Inhibitors Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 94. North America Neuraminidase Inhibitors Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 95. Europe Neuraminidase Inhibitors Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 96. Europe Neuraminidase Inhibitors Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 97. Asia Pacific Neuraminidase Inhibitors Drug Sales Forecast by Region (2025-2030) & (Kilotons)
Table 98. Asia Pacific Neuraminidase Inhibitors Drug Market Size Forecast by Region (2025-2030) & (M USD)
Table 99. South America Neuraminidase Inhibitors Drug Sales Forecast by Country (2025-2030) & (Kilotons)
Table 100. South America Neuraminidase Inhibitors Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 101. Middle East and Africa Neuraminidase Inhibitors Drug Consumption Forecast by Country (2025-2030) & (Units)
Table 102. Middle East and Africa Neuraminidase Inhibitors Drug Market Size Forecast by Country (2025-2030) & (M USD)
Table 103. Global Neuraminidase Inhibitors Drug Sales Forecast by Type (2025-2030) & (Kilotons)
Table 104. Global Neuraminidase Inhibitors Drug Market Size Forecast by Type (2025-2030) & (M USD)
Table 105. Global Neuraminidase Inhibitors Drug Price Forecast by Type (2025-2030) & (USD/Ton)
Table 106. Global Neuraminidase Inhibitors Drug Sales (Kilotons) Forecast by Application (2025-2030)
Table 107. Global Neuraminidase Inhibitors Drug Market Size Forecast by Application (2025-2030) & (M USD)
LIST OF FIGURES
Figure 1. Product Picture of Neuraminidase Inhibitors Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neuraminidase Inhibitors Drug Market Size (M USD), 2019-2030
Figure 5. Global Neuraminidase Inhibitors Drug Market Size (M USD) (2019-2030)
Figure 6. Global Neuraminidase Inhibitors Drug Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neuraminidase Inhibitors Drug Market Size by Country (M USD)
Figure 11. Neuraminidase Inhibitors Drug Sales Share by Manufacturers in 2023
Figure 12. Global Neuraminidase Inhibitors Drug Revenue Share by Manufacturers in 2023
Figure 13. Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Neuraminidase Inhibitors Drug Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Neuraminidase Inhibitors Drug Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Neuraminidase Inhibitors Drug Market Share by Type
Figure 18. Sales Market Share of Neuraminidase Inhibitors Drug by Type (2019-2024)
Figure 19. Sales Market Share of Neuraminidase Inhibitors Drug by Type in 2023
Figure 20. Market Size Share of Neuraminidase Inhibitors Drug by Type (2019-2024)
Figure 21. Market Size Market Share of Neuraminidase Inhibitors Drug by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Neuraminidase Inhibitors Drug Market Share by Application
Figure 24. Global Neuraminidase Inhibitors Drug Sales Market Share by Application (2019-2024)
Figure 25. Global Neuraminidase Inhibitors Drug Sales Market Share by Application in 2023
Figure 26. Global Neuraminidase Inhibitors Drug Market Share by Application (2019-2024)
Figure 27. Global Neuraminidase Inhibitors Drug Market Share by Application in 2023
Figure 28. Global Neuraminidase Inhibitors Drug Sales Growth Rate by Application (2019-2024)
Figure 29. Global Neuraminidase Inhibitors Drug Sales Market Share by Region (2019-2024)
Figure 30. North America Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Neuraminidase Inhibitors Drug Sales Market Share by Country in 2023
Figure 32. U.S. Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Neuraminidase Inhibitors Drug Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Neuraminidase Inhibitors Drug Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Neuraminidase Inhibitors Drug Sales Market Share by Country in 2023
Figure 37. Germany Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Neuraminidase Inhibitors Drug Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Neuraminidase Inhibitors Drug Sales Market Share by Region in 2023
Figure 44. China Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Neuraminidase Inhibitors Drug Sales and Growth Rate (Kilotons)
Figure 50. South America Neuraminidase Inhibitors Drug Sales Market Share by Country in 2023
Figure 51. Brazil Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Neuraminidase Inhibitors Drug Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Neuraminidase Inhibitors Drug Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Neuraminidase Inhibitors Drug Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Neuraminidase Inhibitors Drug Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Neuraminidase Inhibitors Drug Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Neuraminidase Inhibitors Drug Market Share Forecast by Type (2025-2030)
Figure 65. Global Neuraminidase Inhibitors Drug Sales Forecast by Application (2025-2030)
Figure 66. Global Neuraminidase Inhibitors Drug Market Share Forecast by Application (2025-2030)
Figure 1. Product Picture of Neuraminidase Inhibitors Drug
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Neuraminidase Inhibitors Drug Market Size (M USD), 2019-2030
Figure 5. Global Neuraminidase Inhibitors Drug Market Size (M USD) (2019-2030)
Figure 6. Global Neuraminidase Inhibitors Drug Sales (Kilotons) & (2019-2030)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential
Figure 10. Neuraminidase Inhibitors Drug Market Size by Country (M USD)
Figure 11. Neuraminidase Inhibitors Drug Sales Share by Manufacturers in 2023
Figure 12. Global Neuraminidase Inhibitors Drug Revenue Share by Manufacturers in 2023
Figure 13. Neuraminidase Inhibitors Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2023
Figure 14. Global Market Neuraminidase Inhibitors Drug Average Price (USD/Ton) of Key Manufacturers in 2023
Figure 15. The Global 5 and 10 Largest Players: Market Share by Neuraminidase Inhibitors Drug Revenue in 2023
Figure 16. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 17. Global Neuraminidase Inhibitors Drug Market Share by Type
Figure 18. Sales Market Share of Neuraminidase Inhibitors Drug by Type (2019-2024)
Figure 19. Sales Market Share of Neuraminidase Inhibitors Drug by Type in 2023
Figure 20. Market Size Share of Neuraminidase Inhibitors Drug by Type (2019-2024)
Figure 21. Market Size Market Share of Neuraminidase Inhibitors Drug by Type in 2023
Figure 22. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 23. Global Neuraminidase Inhibitors Drug Market Share by Application
Figure 24. Global Neuraminidase Inhibitors Drug Sales Market Share by Application (2019-2024)
Figure 25. Global Neuraminidase Inhibitors Drug Sales Market Share by Application in 2023
Figure 26. Global Neuraminidase Inhibitors Drug Market Share by Application (2019-2024)
Figure 27. Global Neuraminidase Inhibitors Drug Market Share by Application in 2023
Figure 28. Global Neuraminidase Inhibitors Drug Sales Growth Rate by Application (2019-2024)
Figure 29. Global Neuraminidase Inhibitors Drug Sales Market Share by Region (2019-2024)
Figure 30. North America Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 31. North America Neuraminidase Inhibitors Drug Sales Market Share by Country in 2023
Figure 32. U.S. Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 33. Canada Neuraminidase Inhibitors Drug Sales (Kilotons) and Growth Rate (2019-2024)
Figure 34. Mexico Neuraminidase Inhibitors Drug Sales (Units) and Growth Rate (2019-2024)
Figure 35. Europe Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 36. Europe Neuraminidase Inhibitors Drug Sales Market Share by Country in 2023
Figure 37. Germany Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 38. France Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 39. U.K. Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 40. Italy Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 41. Russia Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 42. Asia Pacific Neuraminidase Inhibitors Drug Sales and Growth Rate (Kilotons)
Figure 43. Asia Pacific Neuraminidase Inhibitors Drug Sales Market Share by Region in 2023
Figure 44. China Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 45. Japan Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 46. South Korea Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 47. India Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 48. Southeast Asia Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 49. South America Neuraminidase Inhibitors Drug Sales and Growth Rate (Kilotons)
Figure 50. South America Neuraminidase Inhibitors Drug Sales Market Share by Country in 2023
Figure 51. Brazil Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 52. Argentina Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 53. Columbia Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 54. Middle East and Africa Neuraminidase Inhibitors Drug Sales and Growth Rate (Kilotons)
Figure 55. Middle East and Africa Neuraminidase Inhibitors Drug Sales Market Share by Region in 2023
Figure 56. Saudi Arabia Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 57. UAE Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 58. Egypt Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 59. Nigeria Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 60. South Africa Neuraminidase Inhibitors Drug Sales and Growth Rate (2019-2024) & (Kilotons)
Figure 61. Global Neuraminidase Inhibitors Drug Sales Forecast by Volume (2019-2030) & (Kilotons)
Figure 62. Global Neuraminidase Inhibitors Drug Market Size Forecast by Value (2019-2030) & (M USD)
Figure 63. Global Neuraminidase Inhibitors Drug Sales Market Share Forecast by Type (2025-2030)
Figure 64. Global Neuraminidase Inhibitors Drug Market Share Forecast by Type (2025-2030)
Figure 65. Global Neuraminidase Inhibitors Drug Sales Forecast by Application (2025-2030)
Figure 66. Global Neuraminidase Inhibitors Drug Market Share Forecast by Application (2025-2030)
